Archives for March 2016

March 2016 - Page 2 of 27 - Money Morning - Only the News You Can Profit From

How to Protect Your Biotech Profits from This Legal Limbo

by

Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.

Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long – 24 to 48 weeks – and arduous.

Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.

Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.

So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.

There's just one big, expensive problem...

One Trade to Profit from P2P Lending's Latest Headwind

by

For several months now, I've been telling you about the dangers of online lending, also known as peer-to-peer (P2P) lending.

Right now, the Supreme Court is giving serious consideration to a case that could undo decades of precedent… and absolutely crush online lenders.

Today, I'm going to tell you why the case could represent a landmark in finance... and more importantly, I'll give you a trade that can deliver profits no matter how the court ultimately rules...